Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.9%

4 terminated/withdrawn out of 31 trials

Success Rate

81.0%

-5.7% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

18%

3 of 17 completed trials have results

Key Signals

4 recruiting3 with results

Enrollment reporting

Analytics

Phase 2
24(85.7%)
Phase 1/2
3(10.7%)
Phase 3
1(3.6%)
28Total
Phase 2(24)
Phase 1/2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials
NCT07126236Phase 2Recruiting

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Role: lead

NCT06284122Phase 3Active Not Recruiting

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Role: collaborator

NCT07624838Recruiting

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Role: lead

NCT02682641Phase 2Active Not Recruiting

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Role: lead

NCT07285590Phase 2Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

Role: lead

NCT07254754Phase 2Recruiting

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

Role: lead

NCT02692248Phase 2Completed

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Role: lead

NCT02012088Phase 2Completed

Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb

Role: lead

NCT03576378Phase 1/2Unknown

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Role: lead

NCT04244331Terminated

DETERMINATION OF THE CELL OF ORIGIN (COO) in LDCGB

Role: lead

NCT04378647Phase 2Unknown

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Role: lead

NCT05049473Phase 2Unknown

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Role: collaborator

NCT01613300Phase 2Completed

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

Role: lead

NCT00662948Phase 2Completed

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Role: collaborator

NCT02267915Phase 2Unknown

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT

Role: lead

NCT02340936Phase 1/2Completed

Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma

Role: lead

NCT02243436Phase 1/2Completed

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Role: lead

NCT01133158Phase 2Completed

R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Role: lead

NCT01848132Phase 2Completed

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Role: lead

NCT02701517Phase 2Terminated

Cyclosporine Plus Methotrexate or Alemtuzumab

Role: lead